---
figid: PMC8166058__pnas.2016904118fig05
figtitle: Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling
  in pancreatic cancer
organisms:
- Homo sapiens
- Mus musculus
- Escherichia coli
- Human immunodeficiency virus 1
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
- Danio rerio
pmcid: PMC8166058
filename: pnas.2016904118fig05.jpg
figlink: /pmc/articles/PMC8166058/figure/fig05/
number: F5
caption: Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit WT RAS in pancreatic
  cancer cells. Schematics illustrating RSK1/NF1 interactions and known mechanisms
  of RSK1-mediated negative feedback on the RAS pathway. Mutant KRAS activates the
  RAF/MEK/ERK/RSK and PI3K/AKT pathways. Upon ERK activation, RSK1 transiently localizes
  to the membrane (). (A) In KRAS-mutant PDAC cells, RSK1 depends on MEK activity
  and NF1/SPRED2 expression to be recruited to the mutant-KRAS interactome on the
  membrane. Membrane-localized RSK1 negatively regulates RAS activation by inhibiting
  the RasGEF, SOS1, and activating the RasGAP, NF1. Compared to mutant RAS, WT RAS
  exhibits greater sensitivity to RasGEFs and RasGAPs; therefore, the RSK1-mediated
  negative feedback mechanism potently inhibits WT RAS but not mutant RAS. (B) Upon
  mutant Kras ablation, decreased SPRED2 expression and ERK-mediated RSK1 phosphoactivation
  disengages the negative feedback exerted on WT RAS by NF1/RSK1, thereby enabling
  RAS-addicted cells to survive.
papertitle: Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling
  in pancreatic cancer.
reftext: Derek K. Cheng, et al. Proc Natl Acad Sci U S A. 2021 May 25;118(21):e2016904118.
year: '2021'
doi: 10.1073/pnas.2016904118
journal_title: Proceedings of the National Academy of Sciences of the United States
  of America
journal_nlm_ta: Proc Natl Acad Sci U S A
publisher_name: National Academy of Sciences
keywords: KRAS | PDAC | NF1 | BioID | RSK
automl_pathway: 0.9512416
figid_alias: PMC8166058__F5
figtype: Figure
redirect_from: /figures/PMC8166058__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8166058__pnas.2016904118fig05.html
  '@type': Dataset
  description: Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit WT RAS in pancreatic
    cancer cells. Schematics illustrating RSK1/NF1 interactions and known mechanisms
    of RSK1-mediated negative feedback on the RAS pathway. Mutant KRAS activates the
    RAF/MEK/ERK/RSK and PI3K/AKT pathways. Upon ERK activation, RSK1 transiently localizes
    to the membrane (). (A) In KRAS-mutant PDAC cells, RSK1 depends on MEK activity
    and NF1/SPRED2 expression to be recruited to the mutant-KRAS interactome on the
    membrane. Membrane-localized RSK1 negatively regulates RAS activation by inhibiting
    the RasGEF, SOS1, and activating the RasGAP, NF1. Compared to mutant RAS, WT RAS
    exhibits greater sensitivity to RasGEFs and RasGAPs; therefore, the RSK1-mediated
    negative feedback mechanism potently inhibits WT RAS but not mutant RAS. (B) Upon
    mutant Kras ablation, decreased SPRED2 expression and ERK-mediated RSK1 phosphoactivation
    disengages the negative feedback exerted on WT RAS by NF1/RSK1, thereby enabling
    RAS-addicted cells to survive.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Mdk
  - ras
  - Hras
  - Kras
  - Rem1
  - Pik3r1
  - Sos1
  - Spred2
  - Spred1
  - Nf1
  - Rps6ka1
  - Ephb2
  - Mapk1
  - Akt1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - SOS1
  - SPRED2
  - SPRED1
  - NF1
  - RPS6KA1
  - EPHB2
  - MAPK1
  - MAPK3
  - AKT1
  - AKT2
  - AKT3
  - Dsor1
  - Mtk
  - Ras64B
  - Ras85D
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Sos
  - Erk7
  - rl
  - Akt
  - rab1ab
  - sos1
  - spred2b
  - spred1
  - nf1a
  - kras
---
